Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

Next Previous
Trial Profile

Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Concizumab (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions; Expanded access; Registrational
  • Acronyms Explorer10
  • Sponsors Novo Nordisk; Novo Nordisk Foundation

Most Recent Events

  • 28 May 2025 Planned number of patients changed from 127 to 153.
  • 28 May 2025 Planned primary completion date changed from 26 Jun 2026 to 14 Sep 2029.
  • 05 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 26 Jun 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top